Camp4 Therapeutics Corp (CAMP) stock
Close on Nov 11, 2026Market cap $263.56MP/E –Yield 0.00%
Camp4 Therapeutics Corp grew revenue 39.9% to $5.32M over the twelve months to Sep 30, 2026. Free cash flow was -$26.41M. At the latest close the market valued the company at $263.56M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $263.56M
- P/E ratio
- –
- Price to sales
- 49.54
- Price to book
- 2.46
- Dividend yield
- 0.00%
- Free cash flow yield
- -10.02%
Fundamentals
- Revenue
- $5.32M
- Net income
- -$121.10M
- EPS, diluted
- -$2.02
- Free cash flow
- -$26.41M
- Book value per share
- $1.36
- Diluted shares
- 79M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $4.33
- Open
- $4.41
- Day's range
- $4.13 – $4.42
- Volume
- 95,223
- Average volume (20 days)
- 147,450
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 2.75
- 52-week range
- $2.90 – $7.75
- RSI (14 days)
- 57.5
- Volatility (1 year)
- 110.2%
- Relative volume
- 0.40×
- WACC
- 17.4%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CAMP | S&P 500 | Difference | CAMP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.4% | -2.4% | +13.8 pts | ||
| 3 months | +0.7% | -1.2% | +1.9 pts | ||
| Year to date | -31.5% | +12.3% | −43.8 pts | ||
| 1 year | +1.7% | +12.4% | −10.8 pts | ||
| 3 years | -41.1% | +78.8% | −119.9 pts | -16.2% | +21.4% |
| 5 years | -98.3% | +75.2% | −173.5 pts | -55.7% | +11.9% |
| 10 years | -98.7% | +311.1% | −409.8 pts | -35.4% | +15.2% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Camp4 Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Update
- Update
About Camp4 Therapeutics
Pharmaceutical Preparations
Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical enterprise focused on discovering and developing regulatory RNA-targeting therapeutics. The organization utilizes its proprietary RAP Platform and antisense oligonucleotides to upregulate gene expression and restore protein levels across central nervous system disorders and other genetic indications. Its lead product candidate is CMP-002, an investigational treatment designed to address SYNGAP1-related developmental and epileptic encephalopathy. Additionally, the company is researching treatments for other encephalopathy indications and metabolic conditions, including urea cycle disorders via candidate CMP-001. Camp4 targets patient populations affected by rare and prevalent haploinsufficient conditions, while partnering with large pharmaceutical organizations such as GlaxoSmithKline to co-develop treatments.
Company profile, executives and historyCamp4 Therapeutics stock: common questions
What is Camp4 Therapeutics's stock price?
CAMP closed at $4.20 on Nov 11, 2026, down 3.00% on the day. Over the past 52 weeks it traded between $2.90 and $7.75.
What is Camp4 Therapeutics's market cap?
Camp4 Therapeutics was worth $263.56M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CAMP's P/E ratio?
Camp4 Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.02), so it has no meaningful P/E ratio.
How much revenue does Camp4 Therapeutics make?
Camp4 Therapeutics reported revenue of $5.32M for the twelve months to Sep 30, 2026, up 39.9% from a year earlier.
Does Camp4 Therapeutics pay a dividend?
No. Camp4 Therapeutics has not paid a cash dividend over the last twelve months.
When does Camp4 Therapeutics report earnings next?
Camp4 Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has CAMP stock performed over the past year?
Including dividends, CAMP returned +1.7% over the past year, against +12.4% for the S&P 500.
How many CAMP shares are sold short?
3M shares were sold short at the latest FINRA report, 6.63% of the float, or 23.7 days of average trading volume.
Who are Camp4 Therapeutics's competitors?
Companies most similar to Camp4 Therapeutics by business, industry and size include PRAX, TRDA, NAMS, XENE, DNTH.
See a number that looks wrong?